Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: a multicentric real-world study (BRIGALK study)

Rearrangements of anaplastic lymphoma kinase gene (ALK) are an oncogenic driver reported in 3 –5% of patients with non-small cell lung cancers (NSCLC) [1]. Patients with ALK rearrangement (ALK-positive) NSCLC are generally younger, are never or light smokers, with a histology of adenocarcinoma and a high risk of central nervous system (CNS) metastases at diagnosis and progression [2,3].

Source: Lung Cancer - August 13, 2019 Category: Cancer & Oncology Authors: Renaud Descourt, Maurice Perol, Ga ëlle Rousseau-Bussac, David Planchard, Bertrand Mennecier, Marie Wislez, Alexis Cortot, Florian Guisier, Loïck Galland, Pascal Dô, Roland Schott, Eric Dansin, Jennifer Arrondeau, Jean-Bernard Auliac, Christos Chouaid Source Type: research